Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Category 2.2 drug abiraterone, a modified androgen synthesis inhibitor. The drug is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in combination with prednisone or prednisolone. This marks the first approval of a modified version of abiraterone in China, expanding treatment options for patients with these conditions.
The NMPA’s approval was granted based on the positive results from Phase I and Phase II clinical studies, which demonstrated the drug’s safety and efficacy in the specified patient populations.- Flcube.com
